75 results
8-K
EX-99.1
RNLX
Renalytix Plc
28 May 24
Departure of Directors or Certain Officers
7:15am
in chronic disease – FDA approval, broad reimbursement, outcomes data and clinical guidelines. We are incredibly grateful to O. James Sterling for his
424B5
RNLX
Renalytix Plc
15 May 24
Prospectus supplement for primary offering
10:09am
additional financing;
our ability to continue as a going concern;
third-party payor reimbursement and coverage decisions;
the performance of our … be compromised if we do not obtain and maintain coverage and adequate reimbursement from third-party payors—Medicare, specifically—for KidneyIntelX.
Payors from
8-K
EX-1.1
RNLX
Renalytix Plc
15 May 24
Entry into a Material Definitive Agreement
9:23am
) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee
8-K
EX-99.1
f90lq7
15 May 24
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
7:00am
424B3
5gtvi7sg
7 May 24
Prospectus supplement
6:29pm
8-K
EX-10.2
s3kujqbuwn
23 Apr 24
Entry into a Material Definitive Agreement
5:00pm
424B5
3odx5gf
9 Apr 24
Prospectus supplement for primary offering
4:31pm
8-K
EX-10.1
f6191xp 5yxxzp6q
13 Mar 24
Entry into a Material Definitive Agreement
7:00am
8-K
xvlcqz3ua
29 Feb 24
Regulation FD Disclosure
6:05am
8-K
EX-99.1
65g84scnsrekc51w4hm
15 Feb 24
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
7:00am
8-K
EX-99.1
ezrn4r8x
17 Jan 24
Update on kidneyIntelX.dkd Local Coverage Determination Consideration
7:15am
8-K
EX-99.1
tc9b 4wk4q58
10 Jan 24
Regulation FD Disclosure
7:15am
8-K
EX-99.1
bni3yvg ud
14 Nov 23
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
12:00am
10-Q
5pttifamwbodw jms
14 Nov 23
Quarterly report
12:00am
DEFR14A
p5xra36lbd bv7g7zhu
13 Nov 23
Revised proxy
5:15pm